Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty
- PMID: 20802316
- DOI: 10.1097/ICO.0b013e3181d92834
Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty
Abstract
Purpose: To evaluate the effect of perilimbal bevacizumab injection on neovascularization at the interface of donor and recipient tissues after deep anterior lamellar keratoplasty (DALK).
Methods: This interventional case series included 4 patients with interface neovascularization after DALK (3 patients with advanced keratoconus and 1 patient with scarring because of herpetic keratitis). Bevacizumab (2.5 mg/0.1 mL) was injected subconjunctivally near the limbus adjacent to the abnormal blood vessels. Depending on regression of new vessels, injections were repeated. If neovascularization occurred in more than 1 quadrant, injections were administered at 2 sites (2.5 mg for each injection). Total corneal neovascularization, longest neovascular length, and degree of neovascular circumference were evaluated by digital slit lamp corneal photography before injection and 1 week, 1, 3, and 6 months afterward.
Results: The mean follow-up period was 14 ± 7.52 months from the first bevacizumab injection. Corneal neovascularization, on average,was 33.70% ± 7.8% (SD) of the total corneal surface before the injections, which decreased to 4.83% ± 3.3% (P = 0.005, t test) at the last follow-up examination. Mean degree of neovascularized circumference decreased from 165 degrees before injection to 77.5 degrees (P = 0.023) at the last follow-up examination. Mean longest neovascularized length decreased from 6.714 mm before injection to 1.497 mm (P = 0.021) at the last follow-up examination. At the end of the study, all patients had clear grafts with no sign of graft failure. Mean best-corrected visual acuity before injection was 20/100, which improved to 20/30 at the last examination.
Conclusions: This small case series suggests that perilimbal bevacizumab injection is safe and effective for partial regression of new blood vessels at the interface of donor and recipient tissues after DALK and may effectively prevent graft rejection.
Similar articles
-
Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique.Cornea. 2011 Feb;30(2):215-8. doi: 10.1097/ICO.0b013e3181e291a6. Cornea. 2011. PMID: 20885312
-
Efficacy of bevacizumab against interface neovascularization after deep anterior lamellar keratoplasty.Cornea. 2012 Feb;31(2):188-90. doi: 10.1097/ICO.0b013e31820ca19e. Cornea. 2012. PMID: 22146545
-
Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.Acta Ophthalmol. 2009 Sep;87(6):653-8. doi: 10.1111/j.1755-3768.2008.01399.x. Epub 2008 Nov 18. Acta Ophthalmol. 2009. PMID: 19021596
-
Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases.Prog Retin Eye Res. 2013 May;34:89-124. doi: 10.1016/j.preteyeres.2013.01.001. Epub 2013 Jan 22. Prog Retin Eye Res. 2013. PMID: 23348581 Review.
-
[Antiangiogenic therapy at the ocular surface: when, what and why?].Ophthalmologe. 2011 Mar;108(3):230-6. doi: 10.1007/s00347-010-2262-0. Ophthalmologe. 2011. PMID: 21271256 Review. German.
Cited by
-
Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno-associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation.J Ophthalmol. 2024 Sep 9;2024:5487973. doi: 10.1155/2024/5487973. eCollection 2024. J Ophthalmol. 2024. PMID: 39286553 Free PMC article. Review.
-
Posterior sub-tenon's bevacizumab injection in diabetic macular edema; a pilot study.Saudi J Ophthalmol. 2015 Oct-Dec;29(4):270-3. doi: 10.1016/j.sjopt.2015.06.002. Epub 2015 Jun 16. Saudi J Ophthalmol. 2015. PMID: 26586977 Free PMC article.
-
Update on the Management of High-Risk Penetrating Keratoplasty.Curr Ophthalmol Rep. 2017 Mar;5(1):38-48. doi: 10.1007/s40135-017-0119-2. Epub 2017 Feb 2. Curr Ophthalmol Rep. 2017. PMID: 28959505 Free PMC article.
-
Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns.Front Med (Lausanne). 2023 Jun 22;10:1210765. doi: 10.3389/fmed.2023.1210765. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37425330 Free PMC article.
-
Approaches toward enhancing survival probability following deep anterior lamellar keratoplasty.Ther Adv Ophthalmol. 2020 Mar 22;12:2515841420913014. doi: 10.1177/2515841420913014. eCollection 2020 Jan-Dec. Ther Adv Ophthalmol. 2020. PMID: 32232195 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources